Literature DB >> 19904236

Characterization of genome integrity for oversized recombinant AAV vector.

Biao Dong1, Hiroyuki Nakai, Weidong Xiao.   

Abstract

Application of recombinant adeno-associated virus (rAAV) in gene therapy has been limited by its packaging capacity. Recent studies suggested that rAAV could achieve persistent transgene expression beyond 4.7-kb packaging limit. To clarify the mechanism leading to transgene expression from oversized rAAV vector, we constructed a series of rAAV vectors with genomes ranging from 2.9 to 7.2 kb. A plasmid replication origin and an ampicillin-resistant marker were included in the vector to facilitate the recovery of circularized, post-transduction AAV genome. Southern dot-blot analysis and silver staining confirmed that rAAVs could be produced at varying vector size. However, the vector yields decreased approximately tenfold for oversized vectors as compared to regular ones. Alkaline Southern blot hybridization suggested that the packaged genomes for oversized vectors were truncated. In the cells transduced by the above vectors, circularized rAAV monomers could be rescued at 24 hours after infection. Few recovered AAV genomes were >5 kb regardless of the initial vector size. In mice receiving the above vectors, larger circularized rAAV genomes could be recovered for oversized vectors at day 21 after vector administration. Our studies suggested that the partially packaged rAAV sequences may complement each other to restore full expression cassette.

Entities:  

Mesh:

Year:  2009        PMID: 19904236      PMCID: PMC2803017          DOI: 10.1038/mt.2009.258

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids.

Authors:  L Cao; Y Liu; M J During; W Xiao
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  AAV vectors, the future workhorse of human gene therapy.

Authors:  R J Samulski
Journal:  Ernst Schering Res Found Workshop       Date:  2003

3.  Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Authors:  H Nakai; S R Yant; T A Storm; S Fuess; L Meuse; M A Kay
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV.

Authors:  R J Samulski; A Srivastava; K I Berns; N Muzyczka
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

5.  Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.

Authors:  Wuping Li; Liqun Zhang; Jarrod S Johnson; Wu Zhijian; Joshua C Grieger; Xiao Ping-Jie; Lauren M Drouin; Mavis Agbandje-McKenna; Raymond J Pickles; R Jude Samulski
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

Review 6.  From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.

Authors:  D Grimm; M A Kay
Journal:  Curr Gene Ther       Date:  2003-08       Impact factor: 4.391

7.  Pathways of removal of free DNA vector ends in normal and DNA-PKcs-deficient SCID mouse hepatocytes transduced with rAAV vectors.

Authors:  Hiroyuki Nakai; Theresa A Storm; Sally Fuess; Mark A Kay
Journal:  Hum Gene Ther       Date:  2003-06-10       Impact factor: 5.695

8.  Replication competent helper functions for recombinant AAV vector generation.

Authors:  L Cao; M During; W Xiao
Journal:  Gene Ther       Date:  2002-09       Impact factor: 5.250

9.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

10.  Clades of Adeno-associated viruses are widely disseminated in human tissues.

Authors:  Guangping Gao; Luk H Vandenberghe; Mauricio R Alvira; You Lu; Roberto Calcedo; Xiangyang Zhou; James M Wilson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more
  105 in total

1.  Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

Authors:  Umut Cagin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency.

Authors:  Matthew Nitzahn; Gabriella Allegri; Suhail Khoja; Brian Truong; Georgios Makris; Johannes Häberle; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

Review 3.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

4.  Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.

Authors:  Lynda S Ostedgaard; David K Meyerholz; Daniel W Vermeer; Philip H Karp; Lindsey Schneider; Curt D Sigmund; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-01       Impact factor: 11.205

Review 5.  In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.

Authors:  Rubul Mout; Moumita Ray; Yi-Wei Lee; Federica Scaletti; Vincent M Rotello
Journal:  Bioconjug Chem       Date:  2017-03-17       Impact factor: 4.774

Review 6.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue.

Authors:  Dan Wang; Li Zhong; M Abu Nahid; Guangping Gao
Journal:  Expert Opin Drug Deliv       Date:  2014-01-03       Impact factor: 6.648

7.  Full-length dystrophin reconstitution with adeno-associated viral vectors.

Authors:  William Lostal; Kasun Kodippili; Yongping Yue; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

8.  Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

Authors:  Yi Lai; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

9.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

Authors:  Jenny McIntosh; Peter J Lenting; Cecilia Rosales; Doyoung Lee; Samira Rabbanian; Deepak Raj; Nishil Patel; Edward G D Tuddenham; Olivier D Christophe; John H McVey; Simon Waddington; Arthur W Nienhuis; John T Gray; Paolo Fagone; Federico Mingozzi; Shang-Zhen Zhou; Katherine A High; Maria Cancio; Catherine Y C Ng; Junfang Zhou; Christopher L Morton; Andrew M Davidoff; Amit C Nathwani
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

Review 10.  Promising and delivering gene therapies for vision loss.

Authors:  Livia S Carvalho; Luk H Vandenberghe
Journal:  Vision Res       Date:  2014-08-02       Impact factor: 1.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.